1. Home
  2. BRN vs BCDA Comparison

BRN vs BCDA Comparison

Compare BRN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnwell Industries Inc.

BRN

Barnwell Industries Inc.

HOLD

Current Price

$1.09

Market Cap

12.2M

Sector

Energy

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.34

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRN
BCDA
Founded
1956
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BRN
BCDA
Price
$1.09
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
53.9K
71.0K
Earning Date
12-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,073,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$1.00
52 Week High
$2.28
$3.20

Technical Indicators

Market Signals
Indicator
BRN
BCDA
Relative Strength Index (RSI) 44.24 44.59
Support Level $1.05 $1.22
Resistance Level $1.16 $1.38
Average True Range (ATR) 0.05 0.10
MACD -0.00 -0.02
Stochastic Oscillator 13.64 32.14

Price Performance

Historical Comparison
BRN
BCDA

About BRN Barnwell Industries Inc.

Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: